Why AI Alone Isn’t Enough for Oligonucleotide Discovery

May 18, 2026

AI is transforming oligonucleotide drug discovery by accelerating sequence design and optimization, but its impact is fundamentally limited by the quality and scale of the underlying data. This article explains why AI alone is not enough - highlighting how data scarcity, inconsistent experimental conditions, and insufficient safety annotations constrain predictive accuracy. It explores the critical need for high-quality, internally generated datasets and standardized workflows to train robust models that can reliably predict efficacy, toxicity, and off-target effects. 

By emphasizing large-scale, well-controlled screening and data-driven experimentation, the piece outlines how a strong data foundation - not algorithms alone - is essential to unlocking the full potential of AI in precision RNA therapeutics and next-generation drug discovery.